Jon Napitupulu

Alumis, a late-stage biopharmaceutical company, has completed patient enrollment for its Phase 2b LUMUS trial of ESK-001, an oral...

Annexon, Inc. has completed enrollment in its Phase 3 ARCHER II trial for vonaprument, a drug targeting dry age-related...

Quanta Therapeutics appointed Vanessa L. Jacoby as Chief Business Officer and Chief Financial Officer, bringing over 25 years of...

Alzamend Neuro, a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, reported positive...

An analysis of genetic and health data from over 700,000 individuals confirms previous estimates of Autosomal Dominant Hypocalcemia type...

Invivyd has appointed Dr. Akiko Iwasaki, a renowned immunobiologist from Yale School of Medicine, to its SPEAR Study Group....

Scancell Holdings plc announced positive Phase 2 SCOPE trial data for its SCIB1/iSCIB1+ Immunobody® DNA active immunotherapies combined with...

SeaStar Medical announced positive preliminary results from its SAVE Surveillance Registry for its QUELIMMUNE therapy in critically ill pediatric...

Abivax reported positive Phase 3 results for obefazimod, a first-in-class oral miR-124 enhancer, in two induction trials for moderate...

IXICO, a neuroscience imaging and biomarker analytics company, has joined the Bio-Hermes-002 study, a collaborative effort aimed at improving...